Collagen Solutions Share Discussion Threads

[ileeman] 25/6/2019 09:53

Should build into results you would think.

[horneblower] 17/6/2019 12:00

Chart looking promising. I bought a few. GL

[sharesoc] 10/6/2019 19:44

The Collagen Solutions presentation from our recent London company seminar can be found in our members area here:

To access the presentation, you'll need to be a full member of ShareSoc, which is a not-for-profit organisation that supports individual shareholders and campaigns for shareholder rights. If you're not already a member you can join here:

Once you've joined, you'll receive an invitation to register for our "members network" private social network, from where you'll be able to access the presentation (and presentations on 100s of other meetings). If you're already a member and have any difficulty accessing the report, please do not hesitate to contact us here:

[martintino] 07/6/2019 15:14

Wow,having a nice share price run today.

[sharesoc] 28/5/2019 16:37

Just to let you know, Collagen present at our Manchester growth company seminar on the 4th June, which may be of interest to current shareholders and potential investors. More details here:

[sharesoc] 22/5/2019 12:19

Collagen Solutions present at our Manchester growth company seminar on the 4th June, which may be of interest to current shareholders and potential investors. More details here:

[moontheloon] 20/5/2019 13:18

Views on recent news? It reads to me that we got CE mark... well jamal comments wise

[martintino] 10/4/2019 13:22

Thanks for the link to a very positive and interesting podcast.

[newtothisgame3] 10/4/2019 08:33

More than Money: Collagen Solutions
09/04/2019 · #Collagen #Solutions (#COS)

[newtothisgame3] 10/4/2019 06:15

Scots biotech firm on course to beat forecasts #COS

[newtothisgame3] 10/4/2019 06:12

Financial turnaround for Glasgow’s #Collagen #Solutions #COS

[pugugly] 05/4/2019 16:52

Anyone any idea which Brett Gordon is building a stake - Goem from <3% to over 4% in 2 days - Some 3.2 million extra share. Not insigificant and much more than marked as trades tracked by ADVFN - Dark pool or NEX or outside the market? Thoughts?

[martintino] 03/4/2019 11:54

Definetly some Bed and ISA action going on with COS imo.
suspect there has been for a while here.
Any thoughts?

[martintino] 28/2/2019 14:58

Update from tuesday.
51 mins onwards is Jamal of COS

[moontheloon] 27/2/2019 12:32

Any comment updates from investor evening ?

[timbo003] 18/2/2019 09:12

Unfortunately I will miss this one as will be in the US, it would be nice it if coincided with news on CE approval for ChondroMimetic


Collagen Solutions plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, announces that Jamal Rushdy will be presenting at an investor evening hosted by Hardman & Co on Tuesday, 26 February at DAC Beachcroft, 100 Fetter Lane, London EC4A 1BN.

The event provides an opportunity for investors to hear about the progress being made by the Company and the potential for its own products going forward. Jamal Rushdy will give a 15 minute presentation followed by a 10 minute Q&A session. Registration is from 5.30pm for a prompt start at 6.00pm.

[moontheloon] 01/2/2019 07:40

Collagen Solutions PLC ChondroMimetic® UpdateSource: UK Regulatory (RNS & others)TIDMCOSRNS Number : 5866OCollagen Solutions PLC31 January 201931 January 2019Collagen Solutions plc("Collagen Solutions", the "Company" or the "Group")ChondroMimetic(R) UpdateDistribution Agreement with Indonesian Partner and Update on CE Mark ProcessCollagen Solutions plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, announces that it has entered into a new license and distribution agreement for ChondroMimetic(R) with an Indonesian partner, PT Rajawali Mutiara Sejahtera ("Rajawali Medika"). Rajawali Medika will collaborate with Collagen Solutions to obtain regulatory approval and launch ChondroMimetic(R) in Indonesia with the potential to expand to several other South East Asian countries. Financial terms of the agreement were not disclosed.Rajawali Medika, based in Jakarta, was founded and managed by highly experienced professionals in sales and marketing of medical devices in the Asia Pacific region. The team's prior experience includes successful hands-on sales and marketing of sports medicine and arthroscopy products with J&J's DePuy Mitek division. Rajawali Medika has a strong network of key orthopaedic surgeons and sales distribution channels in South East Asian countries, experience in conducting professional education programmes and workshops, as well as experience in regulatory affairs to achieve speed to market.ChondroMimetic(R) is a minimally-invasive surgically placed scaffold for the repair of cartilage defects in the knee, backed by positive results of an eight-year clinical extension study reported in Q1 2018. The Company has made a submission for a CE Mark for ChondroMimetic(R) and is currently awaiting further feedback from the Notified Body reviewing the submission. The timing of the CE Mark approval is subject to a due process to be undertaken by the Regulatory Authority, and the previously stated timing of approval by the fiscal year end is therefore uncertain. ChondroMimetic(R) is not currently approved for sale in any markets.Jamal Rushdy, CEO, commented: "We are pleased to enter the partnership agreement with Rajawali Medika for Chondromimetic in South East Asia. We will benefit enormously from both their in-depth expertise in the area of sports medicine procedures as well as their regional presence. This agreement adds to other distributor agreements that we have been putting in place in Asia and Europe in order to initiate our launch of Chondromimetic soon after we obtain regulatory approval. We are currently awaiting feedback regarding our CE Mark submission and we will provide an update once new information becomes available and certainly no later than our proposed April trading update."Enquiries:Collagen Solutions Plc Jamal Rushdy, CEO Via Walbrook Hilary Spence, CFO Cenkos Securities Plc (Nominated Adviser and Broker) Steve Cox (Corporate Finance) Tel: [phone] Giles Balleny Walbrook PR Ltd Tel: [phone] or [e-mail] Anna Dunphy Mob: [phone] Helen Cresswell Mob: [phone] This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.ENDUPDEAKFEDEKNEFF(END) Dow Jones NewswiresJanuary 31, 2019 02:00 ET (07:00 GMT)

[gwr7] 21/1/2019 16:59

In 2016 they announced their target to increase revenue by 5 times in 5 years, from £3.24m in FY2016 to £16.2m in FY 2021.

The fancy new target preceded a dilutive conditional placing, open offer and a private bond/warrants subscription.

So how are they performing against their target?

Well in the first 2 years they added £0.3m so in the next 3 years they’ll need to be adding £12.7m to the FY2018 3.5m revenue.

In other words the target has gone from 5 times revenue in 5 years to 4.6 times revenue in 3 years which would be spectacular growth indeed.

It could be time to get excited, unless you’re of a sceptical disposition.

[hyperboreus] 15/1/2019 08:06

Interesting RNS this morning continuing the run of positive news flow recently:



A quick bit of research on Olaregen Therapeutix Inc revealed this transaction just one week ago:

[pugugly] 07/1/2019 17:25

And news was leaking as share price bounce was before 3:45pm - But the regulators will do nothing as usual !! Still however well below my average selling price

And where are they going to get the balance of the funds it appears they are required to invest under the terms of the grant - That is if I am reading the rns correctly

"The grant totals GBP1.54m to support the Company's future investment of up to GBP3.96m across its next generation proprietary product development pipeline. "

[timbo003] 07/1/2019 17:00

So, it was the non-dilutive funding 😁

[timbo003] 07/1/2019 14:18

These are beginning to twitch, maybe news afoot on ChondroMimetic or the non-dilutive funding, or perhaps L&G are at last out.

[timbo003] 05/12/2018 18:29

There is a new Proactive video with Jamal and Hilary here: